Bixler E O, Kales A, Santen R, Vela-Bueno A, Soldatos C R, Kotas D M
Res Commun Chem Pathol Pharmacol. 1976 Jul;14(3):421-9.
Sleep stages and release patterns for growth hormone (GH), luteinizing hormone (LH) and prolactin were evaluated in two subjects during a three week period in which flurazepam 30 mg was administered nightly. Sleep stages were monitored throughout the placebo-baseline, drug and placebo-withdrawal conditions. Blood samples were obtained on nights three and four of baseline, after two and three weeks of drug administration and following extended drug withdrawal. In both subjects, flurazepam produced a marked suppression in stages 3 and 4 (slow wave) sleep which was maintained throughout the drug administration period. Following withdrawal, there was a slight increase in slow wave sleep above baseline levels. With all three hormones, no clear cut changes were observed in mean nightly output, pulse amplitude and pulse frequency from baseline to the drug and the withdrawal conditions. Thus, the decrease in slow wave sleep produced by administering flurazepam 30 mg was not accompanied by any clear cut changes in GH, LH or prolactin.
在为期三周的时间里，对两名受试者的睡眠阶段以及生长激素（GH）、促黄体生成素（LH）和催乳素的释放模式进行了评估。在此期间，每晚服用30毫克氟西泮。在安慰剂基线期、用药期和安慰剂撤药期全程监测睡眠阶段。在基线期的第三和第四晚、用药两周和三周后以及延长撤药期后采集血样。在两名受试者中，氟西泮均使3期和4期（慢波）睡眠显著减少，且在整个用药期间持续存在。撤药后，慢波睡眠较基线水平略有增加。对于所有这三种激素，从基线期到用药期及撤药期，平均每晚分泌量、脉冲幅度和脉冲频率均未观察到明显变化。因此，服用30毫克氟西泮导致的慢波睡眠减少并未伴随GH、LH或催乳素的任何明显变化。
